Production (Stage)
Mydecine Innovations Group Inc.
MYCO
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.82M | -2.36M | -9.15M | -8.57M | -8.50M |
| Total Depreciation and Amortization | -- | -- | 0.00 | 900.00 | 3.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 539.70K | 559.90K | 3.98M | 3.88M | 3.80M |
| Change in Net Operating Assets | 1.27M | 1.77M | 4.91M | 4.38M | 3.78M |
| Cash from Operations | -7.00K | -26.40K | -257.50K | -309.60K | -914.80K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 0.00 | 0.00 | 18.80K |
| Cash from Investing | -- | -- | 0.00 | 0.00 | 18.80K |
| Total Debt Issued | -- | -- | 110.00K | 110.00K | 110.00K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 283.00K | 284.00K | 1.11M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 288.90K | 289.60K | 903.40K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.00K | -26.40K | 31.30K | -20.00K | 7.40K |